683 related articles for article (PubMed ID: 24706635)
1. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
[TBL] [Abstract][Full Text] [Related]
2. Amphiphilic peptide dendritic copolymer-doxorubicin nanoscale conjugate self-assembled to enzyme-responsive anti-cancer agent.
Li N; Li N; Yi Q; Luo K; Guo C; Pan D; Gu Z
Biomaterials; 2014 Nov; 35(35):9529-45. PubMed ID: 25145854
[TBL] [Abstract][Full Text] [Related]
3. The potential of self-assembled, pH-responsive nanoparticles of mPEGylated peptide dendron-doxorubicin conjugates for cancer therapy.
She W; Luo K; Zhang C; Wang G; Geng Y; Li L; He B; Gu Z
Biomaterials; 2013 Feb; 34(5):1613-23. PubMed ID: 23195490
[TBL] [Abstract][Full Text] [Related]
4. Biodegradable and amphiphilic block copolymer-doxorubicin conjugate as polymeric nanoscale drug delivery vehicle for breast cancer therapy.
Yang Y; Pan D; Luo K; Li L; Gu Z
Biomaterials; 2013 Nov; 34(33):8430-43. PubMed ID: 23896006
[TBL] [Abstract][Full Text] [Related]
5. Dendronized heparin-doxorubicin conjugate based nanoparticle as pH-responsive drug delivery system for cancer therapy.
She W; Li N; Luo K; Guo C; Wang G; Geng Y; Gu Z
Biomaterials; 2013 Mar; 34(9):2252-64. PubMed ID: 23298778
[TBL] [Abstract][Full Text] [Related]
6. DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells.
Wang J; Li N; Cao L; Gao C; Zhang Y; Shuai Q; Xie J; Luo K; Yang J; Gu Z
J Mater Chem B; 2020 Feb; 8(6):1157-1170. PubMed ID: 31951231
[TBL] [Abstract][Full Text] [Related]
7. A duplex oligodeoxynucleotide-dendrimer bioconjugate as a novel delivery vehicle for doxorubicin in in vivo cancer therapy.
Lee IH; Yu MK; Kim IH; Lee JH; Park TG; Jon S
J Control Release; 2011 Oct; 155(1):88-95. PubMed ID: 20854858
[TBL] [Abstract][Full Text] [Related]
8. Enzyme-responsive doxorubicin release from dendrimer nanoparticles for anticancer drug delivery.
Lee SJ; Jeong YI; Park HK; Kang DH; Oh JS; Lee SG; Lee HC
Int J Nanomedicine; 2015; 10():5489-503. PubMed ID: 26357473
[TBL] [Abstract][Full Text] [Related]
9. RGD peptide-modified multifunctional dendrimer platform for drug encapsulation and targeted inhibition of cancer cells.
He X; Alves CS; Oliveira N; Rodrigues J; Zhu J; Bányai I; Tomás H; Shi X
Colloids Surf B Biointerfaces; 2015 Jan; 125():82-9. PubMed ID: 25437067
[TBL] [Abstract][Full Text] [Related]
10. Targeted and pH-responsive delivery of doxorubicin to cancer cells using multifunctional dendrimer-modified multi-walled carbon nanotubes.
Wen S; Liu H; Cai H; Shen M; Shi X
Adv Healthc Mater; 2013 Sep; 2(9):1267-76. PubMed ID: 23447549
[TBL] [Abstract][Full Text] [Related]
11. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy.
Zhang C; Pan D; Li J; Hu J; Bains A; Guys N; Zhu H; Li X; Luo K; Gong Q; Gu Z
Acta Biomater; 2017 Jun; 55():153-162. PubMed ID: 28259838
[TBL] [Abstract][Full Text] [Related]
12. Development of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral release.
Wang K; Zhang X; Zhang L; Qian L; Liu C; Zheng J; Jiang Y
Drug Deliv; 2015 May; 22(3):389-99. PubMed ID: 24670095
[TBL] [Abstract][Full Text] [Related]
13. Preparation and in vitro characterization of pluronic-attached polyamidoamine dendrimers for drug delivery.
Gu Z; Wang M; Fang Q; Zheng H; Wu F; Lin D; Xu Y; Jin Y
Drug Dev Ind Pharm; 2015 May; 41(5):812-8. PubMed ID: 24745851
[TBL] [Abstract][Full Text] [Related]
14. Novel water-soluble and pH-responsive anticancer drug nanocarriers: doxorubicin-PAMAM dendrimer conjugates attached to superparamagnetic iron oxide nanoparticles (IONPs).
Chang Y; Meng X; Zhao Y; Li K; Zhao B; Zhu M; Li Y; Chen X; Wang J
J Colloid Interface Sci; 2011 Nov; 363(1):403-9. PubMed ID: 21821262
[TBL] [Abstract][Full Text] [Related]
15. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
[TBL] [Abstract][Full Text] [Related]
16. Peptide-conjugated PAMAM for targeted doxorubicin delivery to transferrin receptor overexpressed tumors.
Han L; Huang R; Liu S; Huang S; Jiang C
Mol Pharm; 2010 Dec; 7(6):2156-65. PubMed ID: 20857964
[TBL] [Abstract][Full Text] [Related]
17. Enzyme-responsive multifunctional magnetic nanoparticles for tumor intracellular drug delivery and imaging.
Yang Y; Aw J; Chen K; Liu F; Padmanabhan P; Hou Y; Cheng Z; Xing B
Chem Asian J; 2011 Jun; 6(6):1381-9. PubMed ID: 21548100
[TBL] [Abstract][Full Text] [Related]
18. In vivo evaluation of a new polymer-lipid hybrid nanoparticle (PLN) formulation of doxorubicin in a murine solid tumor model.
Wong HL; Rauth AM; Bendayan R; Wu XY
Eur J Pharm Biopharm; 2007 Mar; 65(3):300-8. PubMed ID: 17156986
[TBL] [Abstract][Full Text] [Related]
19. mPEGylated solanesol micelles as redox-responsive nanocarriers with synergistic anticancer effect.
Qin B; Liu L; Wu X; Liang F; Hou T; Pan Y; Song S
Acta Biomater; 2017 Dec; 64():211-222. PubMed ID: 28963017
[TBL] [Abstract][Full Text] [Related]
20. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
